Human Papillomavirus Vaccines: Who Should Get Them and Why?
In 2006, the first of two vaccines for human papillomavirus (HPV) prevention was approved for use in several countries. This has prompted great attention to be paid to HPV infections and their consequences. As the genital HPV types are acquired sexually, acceptability to the public of a vaccine to prevent a sexually transmitted infection (STI) will be an important issue in ensuring good uptake of the vaccine by those who would most benefit.
KeywordsCervical Cancer Sexually Transmitted Infection Genital Wart Recurrent Respiratory Papillomatosis Recurrent Respiratory Papillomatosis Patient
Unable to display preview. Download preview PDF.
- Block SL, Nolan T, Sattler C, Barr E, Giacoletti KED, and Marchant CD, et al. (2006). Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics, 118:2135–2145.PubMedCrossRefGoogle Scholar
- Dobson S, Deeks S, and Money D. (2007). National advisory committee on immunization (NACI) statement on human papillomavirus vaccine. Can Commun Dis Rep, 33:1–32.Google Scholar
- Dubin G for the HPV Vaccine Adolescent Study Investigators, GlaxoSmithKline Biologicals, Rixensart, Belgium. (2005) Enhanced immunogenicity of a candidate human papillomavirus (HPV) 16/18 L1 virus-like particle vaccine (VLP) with novel ASO4 adjuvant in pre-teens/adolescents. Abstract No: 4042. Poster presented at ICAAC 2005.Google Scholar
- Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, and Schuind A et al. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet, 364:1757–1765.PubMedCrossRefGoogle Scholar
- Harper DM, Franco EL, Wheeler C, Moscicki A, Romanowski B, and Roteli-Martins CM et al. (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet, 367:1247–1255.PubMedCrossRefGoogle Scholar
- Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, and Giuliano AR, et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6:271–278.PubMedCrossRefGoogle Scholar
- Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, and Iversen OE, et al. (2006b). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer, 95:1459–1466.PubMedCrossRefGoogle Scholar
- World Health Organization. (2005). Preventing Chronic Diseases: A Vital Investment. WHO Global Report, Geneva.Google Scholar